 Benedetto Mungo
Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenocarcinoma | 10 | 2026 | 926 | 3.260 |
Why?
| | Esophageal Neoplasms | 15 | 2025 | 348 | 2.620 |
Why?
| | Stomach Neoplasms | 3 | 2025 | 128 | 2.270 |
Why?
| | Esophagectomy | 15 | 2024 | 135 | 2.120 |
Why?
| | Databases, Factual | 11 | 2025 | 1491 | 1.590 |
Why?
| | Lymph Node Excision | 3 | 2024 | 173 | 1.240 |
Why?
| | Pancreatic Neoplasms | 6 | 2025 | 928 | 1.220 |
Why?
| | Neoadjuvant Therapy | 8 | 2025 | 467 | 1.170 |
Why?
| | Thoracic Surgery, Video-Assisted | 3 | 2016 | 56 | 0.990 |
Why?
| | Robotic Surgical Procedures | 2 | 2022 | 185 | 0.990 |
Why?
| | Time-to-Treatment | 3 | 2025 | 251 | 0.970 |
Why?
| | Survival Rate | 11 | 2026 | 2094 | 0.950 |
Why?
| | Laparoscopy | 6 | 2024 | 481 | 0.950 |
Why?
| | Carcinoma, Pancreatic Ductal | 4 | 2025 | 293 | 0.850 |
Why?
| | Chemoradiotherapy | 2 | 2024 | 239 | 0.850 |
Why?
| | Metastasectomy | 1 | 2024 | 19 | 0.840 |
Why?
| | Gallbladder Neoplasms | 1 | 2024 | 20 | 0.840 |
Why?
| | Induction Chemotherapy | 1 | 2024 | 88 | 0.830 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2024 | 69 | 0.810 |
Why?
| | Peritoneal Neoplasms | 1 | 2024 | 104 | 0.790 |
Why?
| | Postoperative Complications | 14 | 2024 | 2977 | 0.740 |
Why?
| | Retrospective Studies | 35 | 2026 | 17325 | 0.740 |
Why?
| | Anastomosis, Surgical | 4 | 2024 | 162 | 0.660 |
Why?
| | Social Determinants of Health | 1 | 2025 | 309 | 0.650 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1969 | 0.640 |
Why?
| | Aged | 34 | 2026 | 26215 | 0.630 |
Why?
| | Liver Neoplasms | 2 | 2024 | 777 | 0.600 |
Why?
| | Hernia, Hiatal | 4 | 2017 | 39 | 0.560 |
Why?
| | Middle Aged | 31 | 2026 | 36302 | 0.530 |
Why?
| | Herniorrhaphy | 3 | 2014 | 76 | 0.520 |
Why?
| | Colectomy | 1 | 2017 | 106 | 0.490 |
Why?
| | Pneumonectomy | 2 | 2016 | 167 | 0.480 |
Why?
| | Follow-Up Studies | 9 | 2025 | 5428 | 0.450 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2023 | 189 | 0.450 |
Why?
| | Colonic Neoplasms | 1 | 2017 | 258 | 0.440 |
Why?
| | Carcinoma, Papillary | 2 | 2025 | 82 | 0.440 |
Why?
| | Pancreatectomy | 4 | 2025 | 289 | 0.410 |
Why?
| | Length of Stay | 10 | 2017 | 1350 | 0.390 |
Why?
| | Gastrectomy | 2 | 2025 | 166 | 0.380 |
Why?
| | Male | 34 | 2026 | 73003 | 0.370 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2025 | 76 | 0.360 |
Why?
| | Female | 38 | 2026 | 79035 | 0.360 |
Why?
| | Lung Neoplasms | 2 | 2016 | 2667 | 0.350 |
Why?
| | Prognosis | 6 | 2026 | 4329 | 0.340 |
Why?
| | Humans | 45 | 2026 | 145763 | 0.330 |
Why?
| | Treatment Outcome | 18 | 2026 | 11793 | 0.320 |
Why?
| | United States | 16 | 2025 | 16123 | 0.320 |
Why?
| | Lymphatic Metastasis | 4 | 2026 | 336 | 0.300 |
Why?
| | Lymph Nodes | 3 | 2024 | 509 | 0.300 |
Why?
| | Esophageal Stenosis | 2 | 2024 | 60 | 0.280 |
Why?
| | Pancreaticoduodenectomy | 3 | 2026 | 137 | 0.270 |
Why?
| | Neoplasm Staging | 4 | 2025 | 1474 | 0.270 |
Why?
| | Operative Time | 4 | 2015 | 181 | 0.250 |
Why?
| | Stomach | 3 | 2024 | 111 | 0.250 |
Why?
| | Esophageal Diseases | 2 | 2017 | 30 | 0.240 |
Why?
| | Adult | 16 | 2026 | 40872 | 0.240 |
Why?
| | Patient Readmission | 3 | 2017 | 772 | 0.240 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2026 | 28 | 0.230 |
Why?
| | Ampulla of Vater | 1 | 2026 | 40 | 0.230 |
Why?
| | Anastomotic Leak | 3 | 2024 | 45 | 0.230 |
Why?
| | Vena Cava, Inferior | 1 | 2026 | 83 | 0.230 |
Why?
| | Hepatectomy | 2 | 2024 | 274 | 0.220 |
Why?
| | Thoracic Surgery | 2 | 2017 | 143 | 0.220 |
Why?
| | Biliary Tract Neoplasms | 1 | 2025 | 31 | 0.210 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8346 | 0.210 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 30 | 0.210 |
Why?
| | Esophagogastric Junction | 1 | 2024 | 55 | 0.210 |
Why?
| | Obesity | 2 | 2015 | 3118 | 0.210 |
Why?
| | General Surgery | 2 | 2017 | 206 | 0.200 |
Why?
| | Quality Improvement | 4 | 2017 | 1296 | 0.200 |
Why?
| | Ischemic Preconditioning | 1 | 2024 | 47 | 0.200 |
Why?
| | Risk Factors | 9 | 2024 | 10917 | 0.190 |
Why?
| | Neoplasm Invasiveness | 2 | 2025 | 508 | 0.190 |
Why?
| | Cholangiocarcinoma | 1 | 2024 | 108 | 0.190 |
Why?
| | Bile Duct Neoplasms | 1 | 2024 | 131 | 0.190 |
Why?
| | Specialties, Surgical | 1 | 2023 | 82 | 0.190 |
Why?
| | Pancreatic Fistula | 1 | 2022 | 35 | 0.180 |
Why?
| | Molecular Targeted Therapy | 1 | 2025 | 440 | 0.170 |
Why?
| | Natural Orifice Endoscopic Surgery | 2 | 2012 | 35 | 0.170 |
Why?
| | Logistic Models | 6 | 2017 | 2139 | 0.170 |
Why?
| | Combined Modality Therapy | 1 | 2024 | 1270 | 0.170 |
Why?
| | Socioeconomic Factors | 1 | 2025 | 1327 | 0.160 |
Why?
| | Body Composition | 1 | 2024 | 693 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 641 | 0.150 |
Why?
| | Hospital Mortality | 5 | 2017 | 1038 | 0.150 |
Why?
| | Surgeons | 1 | 2023 | 340 | 0.140 |
Why?
| | Age Factors | 5 | 2025 | 3346 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1547 | 0.140 |
Why?
| | Thoracotomy | 2 | 2016 | 88 | 0.140 |
Why?
| | Reoperation | 3 | 2016 | 637 | 0.140 |
Why?
| | Sarcoma | 2 | 2026 | 207 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 981 | 0.140 |
Why?
| | Esophageal Mucosa | 1 | 2016 | 22 | 0.120 |
Why?
| | Esophagoplasty | 1 | 2016 | 2 | 0.120 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2016 | 70 | 0.120 |
Why?
| | Optical Imaging | 1 | 2016 | 62 | 0.120 |
Why?
| | Body Mass Index | 2 | 2015 | 2447 | 0.120 |
Why?
| | Specialization | 1 | 2017 | 137 | 0.120 |
Why?
| | Conversion to Open Surgery | 1 | 2016 | 22 | 0.120 |
Why?
| | Lymphatic Vessels | 1 | 2016 | 63 | 0.120 |
Why?
| | Pleurodesis | 1 | 2014 | 3 | 0.110 |
Why?
| | Thoracic Diseases | 1 | 2014 | 11 | 0.110 |
Why?
| | Talc | 1 | 2014 | 9 | 0.110 |
Why?
| | Hepatic Artery | 1 | 2014 | 53 | 0.110 |
Why?
| | Tissue Adhesions | 1 | 2014 | 34 | 0.110 |
Why?
| | Thinness | 1 | 2015 | 100 | 0.110 |
Why?
| | Matched-Pair Analysis | 1 | 2014 | 37 | 0.110 |
Why?
| | Respiration Disorders | 1 | 2014 | 78 | 0.100 |
Why?
| | Endometriosis | 1 | 2014 | 58 | 0.100 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2014 | 89 | 0.100 |
Why?
| | Leukocyte Count | 1 | 2014 | 318 | 0.100 |
Why?
| | Standard of Care | 1 | 2014 | 81 | 0.100 |
Why?
| | Thoracic Surgical Procedures | 1 | 2014 | 94 | 0.100 |
Why?
| | Esophageal Achalasia | 1 | 2013 | 29 | 0.100 |
Why?
| | Postoperative Period | 1 | 2014 | 351 | 0.100 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 112 | 0.100 |
Why?
| | Health Services Needs and Demand | 1 | 2014 | 280 | 0.090 |
Why?
| | Quality Indicators, Health Care | 1 | 2015 | 336 | 0.090 |
Why?
| | Gastroscopes | 1 | 2012 | 3 | 0.090 |
Why?
| | Surgical Stapling | 1 | 2012 | 15 | 0.090 |
Why?
| | Jejunum | 1 | 2012 | 37 | 0.090 |
Why?
| | Urinary Tract Infections | 1 | 2014 | 210 | 0.090 |
Why?
| | Rothmund-Thomson Syndrome | 1 | 2011 | 1 | 0.090 |
Why?
| | Fundoplication | 3 | 2017 | 52 | 0.080 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 329 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2015 | 587 | 0.080 |
Why?
| | Catheterization | 1 | 2011 | 184 | 0.080 |
Why?
| | Ileum | 1 | 2011 | 112 | 0.080 |
Why?
| | Venous Thromboembolism | 1 | 2014 | 328 | 0.080 |
Why?
| | Rectum | 1 | 2011 | 182 | 0.080 |
Why?
| | Neoplasms | 2 | 2015 | 2913 | 0.070 |
Why?
| | Decision Support Techniques | 1 | 2013 | 480 | 0.070 |
Why?
| | Weight Loss | 1 | 2014 | 859 | 0.070 |
Why?
| | Constriction, Pathologic | 2 | 2024 | 249 | 0.070 |
Why?
| | Young Adult | 4 | 2025 | 14251 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1582 | 0.060 |
Why?
| | Time Factors | 4 | 2024 | 7133 | 0.060 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2026 | 28 | 0.060 |
Why?
| | Biomarkers | 2 | 2014 | 4302 | 0.060 |
Why?
| | Vascular Patency | 1 | 2026 | 121 | 0.060 |
Why?
| | Pandemics | 2 | 2025 | 1711 | 0.060 |
Why?
| | Adolescent | 4 | 2025 | 22573 | 0.050 |
Why?
| | Feasibility Studies | 3 | 2016 | 1115 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2026 | 427 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2016 | 528 | 0.050 |
Why?
| | Anthropometry | 1 | 2024 | 206 | 0.050 |
Why?
| | Carcinoma, Renal Cell | 1 | 2026 | 230 | 0.050 |
Why?
| | Odds Ratio | 2 | 2016 | 1083 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2026 | 414 | 0.040 |
Why?
| | Lung | 1 | 2014 | 4116 | 0.040 |
Why?
| | Risk Assessment | 2 | 2024 | 3752 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2024 | 645 | 0.040 |
Why?
| | Models, Animal | 2 | 2012 | 392 | 0.040 |
Why?
| | Equipment Design | 2 | 2012 | 525 | 0.040 |
Why?
| | Comorbidity | 2 | 2014 | 1662 | 0.040 |
Why?
| | Swine | 2 | 2012 | 826 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2933 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1329 | 0.030 |
Why?
| | Gastric Fundus | 1 | 2017 | 2 | 0.030 |
Why?
| | Indocyanine Green | 1 | 2016 | 42 | 0.030 |
Why?
| | Registries | 1 | 2025 | 2410 | 0.030 |
Why?
| | Maryland | 1 | 2016 | 67 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3634 | 0.030 |
Why?
| | Infant | 2 | 2025 | 10090 | 0.030 |
Why?
| | Sierra Leone | 1 | 2014 | 3 | 0.030 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2015 | 44 | 0.030 |
Why?
| | Breast Diseases | 1 | 2014 | 23 | 0.030 |
Why?
| | Baltimore | 1 | 2015 | 72 | 0.030 |
Why?
| | Fluorescent Dyes | 1 | 2016 | 334 | 0.030 |
Why?
| | Uterine Diseases | 1 | 2014 | 18 | 0.030 |
Why?
| | Esophagoscopy | 1 | 2016 | 223 | 0.030 |
Why?
| | Gastroplasty | 1 | 2014 | 32 | 0.030 |
Why?
| | Hospital Charges | 1 | 2013 | 46 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1378 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 536 | 0.020 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2014 | 217 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 770 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2013 | 143 | 0.020 |
Why?
| | Remission Induction | 1 | 2013 | 306 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1330 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2013 | 105 | 0.020 |
Why?
| | Developing Countries | 1 | 2014 | 317 | 0.020 |
Why?
| | Malnutrition | 1 | 2013 | 86 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 337 | 0.020 |
Why?
| | Gastroesophageal Reflux | 1 | 2014 | 237 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2014 | 327 | 0.020 |
Why?
| | Hypothyroidism | 1 | 2011 | 68 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 653 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 1139 | 0.020 |
Why?
| | Colonic Diseases | 1 | 2011 | 37 | 0.020 |
Why?
| | Child | 2 | 2025 | 22739 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1897 | 0.020 |
Why?
| | Health Status | 1 | 2016 | 835 | 0.020 |
Why?
| | Anal Canal | 1 | 2011 | 102 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 11868 | 0.020 |
Why?
| | Overweight | 1 | 2015 | 614 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2014 | 714 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2013 | 426 | 0.020 |
Why?
| | Pneumonia | 1 | 2014 | 636 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 995 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2874 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 920 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5922 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 6032 | 0.010 |
Why?
| | Heart Failure | 1 | 2013 | 2326 | 0.010 |
Why?
| | Animals | 2 | 2012 | 38097 | 0.010 |
Why?
|
|
Mungo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|